JP2023512664A5 - - Google Patents

Info

Publication number
JP2023512664A5
JP2023512664A5 JP2022545405A JP2022545405A JP2023512664A5 JP 2023512664 A5 JP2023512664 A5 JP 2023512664A5 JP 2022545405 A JP2022545405 A JP 2022545405A JP 2022545405 A JP2022545405 A JP 2022545405A JP 2023512664 A5 JP2023512664 A5 JP 2023512664A5
Authority
JP
Japan
Prior art keywords
independently
compound according
alkyl
compound
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022545405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512664A (ja
JP7785004B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/015449 external-priority patent/WO2021154966A1/en
Publication of JP2023512664A publication Critical patent/JP2023512664A/ja
Publication of JP2023512664A5 publication Critical patent/JP2023512664A5/ja
Priority to JP2025146979A priority Critical patent/JP2025175030A/ja
Application granted granted Critical
Publication of JP7785004B2 publication Critical patent/JP7785004B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022545405A 2020-01-29 2021-01-28 皮膚障害の治療に使用するための化合物及び組成物 Active JP7785004B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025146979A JP2025175030A (ja) 2020-01-29 2025-09-04 皮膚障害の治療に使用するための化合物及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062967500P 2020-01-29 2020-01-29
US62/967,500 2020-01-29
PCT/US2021/015449 WO2021154966A1 (en) 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025146979A Division JP2025175030A (ja) 2020-01-29 2025-09-04 皮膚障害の治療に使用するための化合物及び組成物

Publications (3)

Publication Number Publication Date
JP2023512664A JP2023512664A (ja) 2023-03-28
JP2023512664A5 true JP2023512664A5 (cg-RX-API-DMAC7.html) 2024-02-06
JP7785004B2 JP7785004B2 (ja) 2025-12-12

Family

ID=77079457

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022545405A Active JP7785004B2 (ja) 2020-01-29 2021-01-28 皮膚障害の治療に使用するための化合物及び組成物
JP2025146979A Pending JP2025175030A (ja) 2020-01-29 2025-09-04 皮膚障害の治療に使用するための化合物及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025146979A Pending JP2025175030A (ja) 2020-01-29 2025-09-04 皮膚障害の治療に使用するための化合物及び組成物

Country Status (12)

Country Link
US (2) US11807621B2 (cg-RX-API-DMAC7.html)
EP (2) EP4574822A3 (cg-RX-API-DMAC7.html)
JP (2) JP7785004B2 (cg-RX-API-DMAC7.html)
KR (1) KR102735703B1 (cg-RX-API-DMAC7.html)
CN (2) CN115335050B (cg-RX-API-DMAC7.html)
AU (1) AU2021212754B2 (cg-RX-API-DMAC7.html)
CA (1) CA3168103A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032872T3 (cg-RX-API-DMAC7.html)
HU (1) HUE071972T2 (cg-RX-API-DMAC7.html)
IL (2) IL295088B2 (cg-RX-API-DMAC7.html)
PL (1) PL4096661T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021154966A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4574822A3 (en) 2020-01-29 2025-08-27 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders
WO2023214375A1 (en) * 2022-05-05 2023-11-09 Kamari Pharma Ltd. Methods of treating dermatological conditions and symptoms thereof
CN117164527B (zh) * 2022-05-25 2026-02-17 大连理工大学 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法
WO2024099404A1 (zh) 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种含氮螺环类化合物、药物组合物以及其用途
CN120202198A (zh) * 2022-11-10 2025-06-24 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
CN117624036A (zh) * 2023-10-30 2024-03-01 爱斯特(成都)生物制药股份有限公司 一种制备6-溴-3-氟-2-吡啶甲醛的方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
DE2961415D1 (en) 1978-05-20 1982-01-28 Bayer Ag Heteroaryloxy-acetamides, process for their preparation and their use as herbicides
US4461896A (en) 1979-02-07 1984-07-24 Norwich Eaton Pharmaceuticals, Inc. 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids
DE3018075A1 (de) 1980-05-10 1981-11-12 Bayer Ag, 5090 Leverkusen Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung
JPS56158702A (en) 1980-05-12 1981-12-07 Nippon Tokushu Noyaku Seizo Kk Herbicide
US4273927A (en) 1980-08-14 1981-06-16 Morton-Norwich Products, Inc. Converting enzyme inhibitor
DE3038652A1 (de) 1980-10-13 1982-05-19 Bayer Ag, 5090 Leverkusen 5-chlor-benzoxazol-2-yl-oxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
DE3038599A1 (de) 1980-10-13 1982-05-19 Bayer Ag, 5090 Leverkusen Substituierte benzazol-2-yl-oxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US4509949A (en) 1983-06-13 1985-04-09 The B. F. Goodrich Company Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
DE3418168A1 (de) 1984-05-16 1985-11-21 Bayer Ag, 5090 Leverkusen 6-chlorbenzazolyloxyacetamide
DE3422861A1 (de) 1984-06-20 1986-01-02 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von heteroaryloxyacetamiden
US5087445A (en) 1989-09-08 1992-02-11 Richardson-Vicks, Inc. Photoprotection compositions having reduced dermal irritation
US5196427A (en) 1990-09-13 1993-03-23 Eli Lilly And Company 3-aryl-4(3H) quinazolinone CCK antagonists and pharmaceutical formulations thereof
US5075313A (en) 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
DE4218433A1 (de) 1992-06-04 1993-12-09 Bayer Ag Fluorbenzoxazolyloxyacetamide
DE4219246A1 (de) 1992-06-12 1993-12-16 Bayer Ag Neue 2-(7-Chlor-2-benzoxazolyloxy)-acetamide
DE4230903A1 (de) 1992-09-16 1994-03-17 Bayer Ag Fluorbenzthiazolyloxyacetamide
FR2707639B1 (fr) 1993-06-30 1995-10-13 Pf Medicament Nouveaux composés indoliques dérivés d'arylamines comme ligands sélectifs des récepteurs 5HT1D et 5HT1B.
US5756502A (en) 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
ES2184960T3 (es) 1996-05-15 2003-04-16 Pfizer Nuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas.
BR9709085A (pt) 1996-05-15 1999-08-03 Pfizer Novas 2,3-dissubstituído-4(3H)-quinazolinonas
US6380204B1 (en) 1997-02-28 2002-04-30 Pfizer Inc Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions
PT968194E (pt) 1997-02-28 2004-08-31 Pfizer Prod Inc Atropisomeros de 3-aril-4(3h)-quinazolinonas e sua utilizacao como antagonistas dos receptores ampa
ATE229004T1 (de) 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JPH11279158A (ja) 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―4―オン誘導体の製造方法
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
DE60017157T2 (de) 1999-09-16 2005-12-22 Curis, Inc., Cambridge Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
US20030219806A1 (en) 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
US20020156253A1 (en) 2000-06-26 2002-10-24 Curtis Rory A.J. 48000 and 52920, novel human calcium channels and uses thereof
GB2372993A (en) 2000-11-03 2002-09-11 Smithkline Beecham Plc Vanilloid Receptor 6
IL155613A0 (en) 2000-12-01 2003-11-23 Bristol Myers Squibb Co Novel human nucleic acid molecules and polypeptides emcoding a novel human ion channel expressed in spinal cord and brain
EP1399558A2 (en) 2001-06-13 2004-03-24 Novartis AG Vanilloid receptor-related nucleic acids and polypeptides
WO2003043961A2 (en) 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
US20040110777A1 (en) 2001-12-03 2004-06-10 Annis Gary David Quinazolinones and pyridinylpyrimidinones for controlling invertebrate pests
US20040009537A1 (en) 2002-01-11 2004-01-15 Jack Roos Methods of modulating and of identifying agents that modulate intracellular calcium
WO2003106435A1 (en) 2002-06-18 2003-12-24 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004041755A2 (en) 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
DE10330157A1 (de) 2003-07-04 2005-02-03 Zf Friedrichshafen Ag Lastschaltgetriebe für Baumaschinen, insbesondere für Baggerlader und Telehandler
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
CA2531766C (en) 2003-09-11 2012-11-27 Tibotec Pharmaceuticals Ltd. Entry inhibitors of the hiv virus
DE10351087A1 (de) 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
EP1687306A1 (en) 2003-11-14 2006-08-09 MERCK SHARP & DOHME LTD. Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
AP2331A (en) 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
WO2005086895A2 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US20050202539A1 (en) 2004-03-11 2005-09-15 Hydra Biosciences System for screening eukaryotic membrane proteins
KR20070012407A (ko) 2004-04-15 2007-01-25 아스텔라스세이야쿠 가부시키가이샤 2-아미노피리미딘 유도체
JP2008501707A (ja) 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
KR101111099B1 (ko) 2004-09-09 2012-02-17 아바야 테크놀러지 코퍼레이션 네트워크 트래픽 보안 방법들 및 시스템들
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
US8916550B2 (en) 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
EP2392328A1 (en) 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
GB0509573D0 (en) 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
AU2006244027A1 (en) 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilloid-1 receptor (VR1)
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US20100152209A1 (en) 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function
WO2008033564A1 (en) 2006-09-15 2008-03-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
US20090306163A1 (en) 2008-06-10 2009-12-10 Pamela Renee Lipkin Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling
KR101034300B1 (ko) 2008-12-02 2011-05-16 고려대학교 산학협력단 Trpv3 활성 억제 약물 및 이의 활용
US8318928B2 (en) * 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
US8318759B2 (en) * 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
EP2630138B1 (en) * 2010-10-21 2015-06-03 Bayer Intellectual Property GmbH 1-(heterocyclic carbonyl)-2-substituted pyrrolidines and their use as fungicides
WO2012058132A1 (en) * 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
TW201336847A (zh) 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
US20140018435A1 (en) 2012-06-06 2014-01-16 University Of Illinois Chicago Transdermal Delivery of Therapeutic Agents Using Poly (Amidoamine) Dendrimers
TWI710558B (zh) 2013-05-01 2020-11-21 瑞士商赫孚孟拉羅股份公司 二雜芳基化合物及其用途
US9617214B2 (en) * 2013-11-08 2017-04-11 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
CA2932396C (en) * 2013-12-03 2022-03-29 Janssen Pharmaceutica Nv Benzamide derivative useful as fasn inhibitors for the treatment of cancer
JP2017100948A (ja) 2014-04-01 2017-06-08 大日本住友製薬株式会社 4−アリールイミダゾール誘導体
EP3204379B1 (en) * 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
WO2016172631A2 (en) * 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
CN107417687A (zh) 2016-05-24 2017-12-01 中国科学院上海药物研究所 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
CN108570038B (zh) 2017-03-08 2021-09-28 中国科学院上海药物研究所 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途
EP4574822A3 (en) 2020-01-29 2025-08-27 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders
WO2023214375A1 (en) * 2022-05-05 2023-11-09 Kamari Pharma Ltd. Methods of treating dermatological conditions and symptoms thereof

Similar Documents

Publication Publication Date Title
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
JP2022529370A5 (cg-RX-API-DMAC7.html)
JP2018534348A5 (cg-RX-API-DMAC7.html)
JP2011509259A5 (cg-RX-API-DMAC7.html)
JP2019517487A5 (cg-RX-API-DMAC7.html)
RU2016105581A (ru) Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
JP2014037426A5 (cg-RX-API-DMAC7.html)
CA2566945A1 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2007508358A5 (cg-RX-API-DMAC7.html)
JP2019516684A5 (cg-RX-API-DMAC7.html)
JP2019517587A5 (cg-RX-API-DMAC7.html)
JP2015509972A5 (cg-RX-API-DMAC7.html)
JP2004518653A (ja) 不安障害を治療する方法
JP2013522230A5 (cg-RX-API-DMAC7.html)
JP2022529061A5 (cg-RX-API-DMAC7.html)
JP2018537513A5 (cg-RX-API-DMAC7.html)
RU2019125177A (ru) Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение
JP2022116304A (ja) 血液がんの治療のためのPPARγアゴニスト
CA2541781A1 (en) 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of respiratory illnesses
JP2023502030A5 (cg-RX-API-DMAC7.html)
TW201034674A (en) Uses of NK receptor antagonists
JP2020510061A5 (cg-RX-API-DMAC7.html)
CN110612286A (zh) 氰基取代的稠合双环衍生物及其制备方法和用途
JP2023549849A5 (cg-RX-API-DMAC7.html)